OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Riccaboni, M.

Seminar Briefing
June 2012

This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar.  It focuses primarily on the reasons for a decline since 2000 in the average number of new drugs launched per year by the pharmaceutical industry.  Factors identified as important include a trend towards targeting more complex and difficult diseases, the need to adapt to dramatic changes in scientific knowledge and in R&D approaches, and substantial changes in both the regulatory and marketing climates.

Mestre-Ferrandiz, J., Mordoh, A. and Sussex, J.

Consulting Report
June 2012

This report provides a clear explanation of the nature of innovation in medicines.  A fully revised and expanded version of the 2005 edition, it updates the literature review of the economics of innovation, traces important innovation that has occurred since 2005, adds new case studies and updates the discussion of competition in pharmaceutical R&D.

Sharma, P.

Seminar Briefing
November 2011

Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures that rely on antibacterials. The current situation is due primarily to two causes: inappropriate use in humans and animals and the decline in the development of new antibacterials, largely because of lower returns on investment in R&D.

Garau, M., Mordoh, A. and Sussex, J.

Consulting Report
April 2011

Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned by Cancer Research UK, explores the interdependence between publicly funded and charity funded medical research.  In particular, it focuses on whether and how changes in the levels of government funding can affect private funding for charities, medical research and the UK economy as a whole.

Garau, M., Towse, A. and Danzon, P.

Occasional Paper
February 2011

This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures. The authors point out that IRP actually encourages higher prices in lower-income countries, can delay marketing/patient access in lower-price countries, and ultimately translates into less investment in R&D. Differential pricing assumes that countries with lower incomes should pay lower prices, encourages the earliest possible marketing in all countries, and provides incentives for innovation.

Grabowski, H.G.

Seminar Briefing
January 2011

Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under a law passed in 2007. The PRV entitles the holder to priority review by the FDA of another drug of the bearer’s choice.  The Vouchers are transferable, i.e., not limited to use by the company that gained approval of the neglected-disease drug.  

Culyer, A.

Briefing
June 2009

In the UK and elsewhere, choices about how to allocate health care resources are guided not only by economic calculations, but also by social value judgments such as those relating to equity and fairness. Factors such as uncertainty around key values, operational feasibility and stakeholder interests also need to be considered. The question of how to combine these inputs is central to the field of health care decision making.

Mattison, N.

Briefing
March 2009

Health technology assessment (HTA) has become a critical basis for pricing and reimbursement decision-making worldwide. In some countries, extensive requirements for data are set out in guidances or regulation and apply to all new prescription medicines; in others, HTA is required of industry or performed by payers only for therapies expected to be particularly costly.  Although the effect of HTA on spending for prescription medicines is studied often, far less attention is given to its effects on decisions about research and development in the biopharmaceutical industries.

Pages